Education
About Us
Working with TipRanks
Follow Us
Kodiak Sciences Inc (KOD)
NASDAQ:KOD
KOD Analyst Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KOD Stock 12 Month Forecast
Average Price Target
$24.17
▲(1.51% Upside)
| Highest Price Target$40.00 | Average Price Target$24.17 | Lowest Price Target$14.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$24→$26
Buy
9.20%
Upside
Reiterated
11/17/25
Kodiak Sciences' Promising Outlook: Buy Rating Affirmed Amid Positive Drug Developments and Strategic AdjustmentsValuation and Risks. With continued: (i) pivotal progress for the ABC platform; (ii) our positive pipeline feedback from retinal KOLs; and (iii) adjusting our conservative POS from 30% to 35% for tarcocimab in DR, heading into the anticipated 1Q26 Phase 3 GLOW2 topline, we reiterate our Buy rating and have raised our price target from $24 to $26 per share.
Barclays
$17
Hold
-28.60%
Downside
Reiterated
11/17/25
Chardan Capital
$14
Hold
-41.20%
Downside
Reiterated
11/17/25
J.P. Morgan
$24→$26
Buy
9.20%
Upside
Reiterated
11/14/25
LifeSci Capital
$40
Buy
68.00%
Upside
Reiterated
11/14/25
Kodiak Sciences: Promising Pipeline and Strategic Differentiation Drive Buy RatingKodiak Sciences (Nasdaq: KOD) reported Q3 earnings and maintained guidance across its pipeline for near-term readouts with and tarcocimab. Recent updates include the Company’s release of 20-week APEX data with KSI-101 (an-IL6/VEGF) in macular edema secondary to inflammaon (MESI) paents, represenng an addional 8-weeks of data off-treatment (note here). Overall, these follow-up data showed incremental further improvements in best corrected visual acuity (BCVA) leers and sustained central subfield thickness (CST) reducons from baseline. As menoned in our note, those data provide further confidence as Kodiak moves towards pivotal PEAK & PINNACLE data with KSI-101, which connue to be expected in 2027, respecvely. This asset connues to be central to our thesis on Kodiak, considering compev e differenaon vs Roche's (Swiss: ROG.SW) compeng IL-6 monospecific asset vamikibart.
Jefferies
$15→$22
Buy
-7.60%
Downside
Reiterated
10/26/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$24→$26
Buy
9.20%
Upside
Reiterated
11/17/25
Kodiak Sciences' Promising Outlook: Buy Rating Affirmed Amid Positive Drug Developments and Strategic AdjustmentsValuation and Risks. With continued: (i) pivotal progress for the ABC platform; (ii) our positive pipeline feedback from retinal KOLs; and (iii) adjusting our conservative POS from 30% to 35% for tarcocimab in DR, heading into the anticipated 1Q26 Phase 3 GLOW2 topline, we reiterate our Buy rating and have raised our price target from $24 to $26 per share.
Barclays
$17
Hold
-28.60%
Downside
Reiterated
11/17/25
Chardan Capital
$14
Hold
-41.20%
Downside
Reiterated
11/17/25
J.P. Morgan
$24→$26
Buy
9.20%
Upside
Reiterated
11/14/25
LifeSci Capital
$40
Buy
68.00%
Upside
Reiterated
11/14/25
Kodiak Sciences: Promising Pipeline and Strategic Differentiation Drive Buy RatingKodiak Sciences (Nasdaq: KOD) reported Q3 earnings and maintained guidance across its pipeline for near-term readouts with and tarcocimab. Recent updates include the Company’s release of 20-week APEX data with KSI-101 (an-IL6/VEGF) in macular edema secondary to inflammaon (MESI) paents, represenng an addional 8-weeks of data off-treatment (note here). Overall, these follow-up data showed incremental further improvements in best corrected visual acuity (BCVA) leers and sustained central subfield thickness (CST) reducons from baseline. As menoned in our note, those data provide further confidence as Kodiak moves towards pivotal PEAK & PINNACLE data with KSI-101, which connue to be expected in 2027, respecvely. This asset connues to be central to our thesis on Kodiak, considering compev e differenaon vs Roche's (Swiss: ROG.SW) compeng IL-6 monospecific asset vamikibart.
Jefferies
$15→$22
Buy
-7.60%
Downside
Reiterated
10/26/25
Best Analysts Covering Kodiak Sciences
1 Month
xxx
Success Rate
3/4 ratings generated profit
Average Return
+0.20%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +0.20% per trade.
3 Months
xxx
Success Rate
3/4 ratings generated profit
Average Return
+8.92%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +8.92% per trade.
1 Year
Success Rate
3/4 ratings generated profit
Average Return
-1.03%
reiterated a buy rating 29 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of -1.03% per trade.
2 Years
xxx
Success Rate
2/4 ratings generated profit
Average Return
-34.15%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -34.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KOD Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
0
0
0
0
2
Buy
0
0
1
2
5
Hold
2
4
5
4
4
Sell
5
3
3
2
1
Strong Sell
0
0
0
0
0
total
7
7
9
8
12
Each month's total comprises the sum of three months' worth of ratings.
KOD Financial Forecast
KOD Stock Forecast FAQ
What is KOD’s average 12-month price target, according to analysts?
Based on analyst ratings, Kodiak Sciences Inc’s 12-month average price target is 24.17.
What is KOD’s upside potential, based on the analysts’ average price target?
Kodiak Sciences Inc has 1.51% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KOD a Buy, Sell or Hold?
Kodiak Sciences Inc has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
What is Kodiak Sciences Inc’s price target?
The average price target for Kodiak Sciences Inc is 24.17. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $14.00. The average price target represents 1.51% Increase from the current price of $23.81.
The highest analyst price target is $40.00 ,the lowest forecast is $14.00. The average price target represents 1.51% Increase from the current price of $23.81.
What do analysts say about Kodiak Sciences Inc?
Kodiak Sciences Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of KOD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.